Exenatide LAR Data Support Initiation of Phase 2 Multi-Dose Study in 2005
November 02 2004 - 7:30AM
PR Newswire (US)
Exenatide LAR Data Support Initiation of Phase 2 Multi-Dose Study
in 2005 Amylin Pharmaceuticals, Inc., (NASDAQ:AMLN), Eli Lilly and
Company (NYSE:LLY) and Alkermes, Inc. (NASDAQ:ALKS) today announced
the decision to initiate a Phase 2 multi-dose study of exenatide
LAR (long-acting release) in patients with type 2 diabetes using a
once-a-week dosing regimen. The multi-dose study is expected to
begin in the first quarter of 2005. Data from the ongoing Phase 2
single-dose study have demonstrated sustained release of exenatide
with no dose-limiting side effects. The injection has been well
tolerated. The single-dose study includes approximately 60 subjects
with type 2 diabetes who were failing to achieve adequate glucose
control using diet and exercise with or without metformin. Subjects
are randomized to receive a single subcutaneous injection of
exenatide LAR at one of four doses or placebo, and are observed for
90 days. At this time, dosing and follow-up observation of the
final exenatide LAR dosage group is ongoing. The goal of the
exenatide LAR program is to develop a sustained release,
subcutaneous injection of exenatide. Exenatide LAR is based on
Alkermes' proprietary Medisorb(R) injectable sustained release drug
delivery technology. About Exenatide Exenatide is the first in a
new class of drugs called incretin mimetics being investigated for
the treatment of type 2 diabetes and appears to exhibit many of the
same effects as the human incretin hormone GLP-1. In June 2004, a
New Drug Application (NDA) for exenatide was submitted to the Food
and Drug Administration (FDA) for regulatory approval. About
Diabetes Diabetes affects an estimated 194 million adults
worldwide(1) and more than 18 million in the United States(2).
Approximately 90-95 percent of those affected have type 2 diabetes,
in which the body does not produce enough insulin and the cells in
the body do not respond normally to the insulin. According to the
US Center for Disease Control and Prevention's National Health and
Nutrition Examination Survey, approximately 60 percent of diabetes
patients do not achieve target A1C levels with their current
treatment regimen. According to the ADA, patients with A1Cs above
target are more likely to develop diabetes-related complications,
such as kidney disease, blindness and heart disease(3). About
Amylin, Lilly and Alkermes Amylin Pharmaceuticals is committed to
improving the lives of people with diabetes and other metabolic
diseases through the discovery, development and commercialization
of innovative, cost-effective medicines. Further information on
Amylin Pharmaceuticals and its pipeline in metabolism is available
at http://www.amylin.com/. Lilly, a leading innovation-driven
corporation, is developing a growing portfolio of first-in-class
and best-in-class pharmaceutical products by applying the latest
research from its own worldwide laboratories and from
collaborations with eminent scientific organizations. Headquartered
in Indianapolis, Ind., Lilly provides answers -- through medicines
and information -- for some of the world's most urgent medical
needs. Additional information about Lilly is available at
http://www.lilly.com/. Alkermes, Inc. is a pharmaceutical company
that develops products based on sophisticated drug delivery
technologies to enhance therapeutic outcomes in major diseases. The
Company's lead commercial product, Risperdal(R) Consta(TM)
[(risperidone) long-acting injection], is the first and only
long-acting atypical antipsychotic medication approved for use in
schizophrenia, and is marketed worldwide by Janssen-Cilag, a
division of Johnson & Johnson. The Company's lead proprietary
product candidate, Vivitrex(R) [(naltrexone) long-acting
injection], is a once-a-month injection for the treatment of
alcohol dependence. Alkermes has a pipeline of extended-release
injectable and pulmonary drug products based on its proprietary
technology and expertise. The Company's headquarters are in
Cambridge, Massachusetts, and it operates research and
manufacturing facilities in Massachusetts and Ohio. Additional
information about Alkermes is available at
http://www.alkermes.com/. This press release contains
forward-looking statements, which involve risks and uncertainties
within the meaning of the Private Securities Litigation Reform Act
of 1995. There can be no assurance that actual results will not
differ materially from the forward-looking statements discussed in
this press release. These forward-looking statements include risks
and uncertainties that current or future clinical trials will
confirm the results referred to in this release or that the
multi-dose trial will commence when planned, risks and
uncertainties inherent in the collaboration with and dependence
upon Lilly, Amylin and/or Alkermes; risks and uncertainties
regarding the drug discovery and development process, including
whether exenatide LAR will receive regulatory approvals or prove to
be commercially successful. These and additional risks and
uncertainties are described more fully in Amylin, Lilly and
Alkermes' filings with the United States Securities and Exchange
Commission, such as their Annual Reports on Form 10-K for the
fiscal year ended December 31, 2003 under the heading "Risk Factors
Related to Our Business," their subsequently filed Quarterly
Reports on Form 10-Q, and Amylin's recently filed Form S-3. The
parties undertake no duty to update forward-looking statements. (1)
The International Diabetes Federation Diabetes Atlas. Available at:
http://www.idf.org/home/index.cfm?unode=3B96906B-C026-2FD3
87B73F80BC22682A. Accessed August 31, 2004. (2) American Diabetes
Association. Available at:
http://www.diabetes.org/about-diabetes.jsp. Accessed August 31,
2004. (3) Saaddine JB, Engelgau MM, Beckles GL, Gregg EW, Thompson
TJ, Narayan KM. A diabetes report card for the United States:
Quality of care in the 1990s. Ann Intern Med. 2002; 136:565-574.
DATASOURCE: Amylin Pharmaceuticals, Inc. CONTACT: Eric Shearin of
Amylin, +1-858-552-2200; or Scott MacGregor of Lilly,
+1-317-651-1494; or Rebecca Peterson of Alkermes, +1-617-583-6378
Web site: http://www.lilly.com/ Web site: http://www.alkermes.com/
Web site: http://www.amylin.com/
Copyright
Amylin Pharmaceuticals, Inc. (MM) (NASDAQ:AMLN)
Historical Stock Chart
From Jun 2024 to Jul 2024
Amylin Pharmaceuticals, Inc. (MM) (NASDAQ:AMLN)
Historical Stock Chart
From Jul 2023 to Jul 2024